
Hidehito Horinouchi/X
Mar 25, 2025, 19:50
Hidehito Horinouchi: Amivantamab plus Lazertinib vs. Osimertinib in 1L EGFRm Advanced NSCLC
Hidehito Horinouchi, Assistant Chief at National Cancer Center Hospital, shared on X:
“Now Out:
MARIPOSA Study: Amivantamab plus Lazertinib vs. Osimertinib in 1L EGFRm Advanced NSCLC – Final OS Results
Presented by Prof. James Yang
- OS HR: 0.75 (95% CI: 0.61–0.92)
- Expected to extend median OS (mOS) by at least 12 months
- NCT Number: NCT04487080″
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 25, 2025, 18:43
Mar 25, 2025, 18:33
Mar 25, 2025, 18:29